Skip to main content

Table 1 Demographics of study populations for WES and WTS analysis

From: Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma

 

All (n = 65)

WES (n = 58)

WTS (n = 48)

Sex, no. (%)

   

 Male

30 (46.2)

25 (43.1)

25 (52.1)

 Female

35 (53.8)

33 (56.9)

23 (47.9)

Age, median years (range)

3.1 (0–14.9)

3.35 (0–14.9)

2.7 (0–10)

Age, no. (%)

   

 < 18 months

18 (27.7)

11 (19.0)

16 (33.3)

 ≥ 18 months

47 (72.3)

47 (81.0)

32 (66.7)

Stage, no. (%)

   

 Localized

30 (46.2)

27 (46.6)

24 (50.0)

 Metastatic

35 (53.8)

31 (53.4)

24 (50.0)

Risk group, no. (%)

   

 High-risk

26 (40.0)

26 (44.8)

16 (33.3)

 Non-high risk

39 (60.0)

32 (55.2)

32 (66.7)

Pathology, no. (%)

   

 Undifferentiated

1 (1.5)

1 (1.7)

1 (2.1)

 Poorly differentiated

25 (38.5)

21 (36.2)

19 (39.6)

 Differentiating

13 (20.0)

11 (19.0)

9 (18.8)

 Ganglioneuroblastoma (GNB)

26 (40.0)

25 (43.1)

19 (39.6)

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us